摘要
目的:制备鲑鱼降钙素(sCT)聚乳酸-羟基乙酸共聚物(PLGA)微球并对其物理性质和体外释放进行考察,为研制sCT的缓释制剂提供科学依据。方法:采用复乳-液中干燥法,以PLGA为成球材料制备sCT微球,用L9(34)正交设计优选微球制备的处方工艺条件,并对所制备微球的外观形态、粒度分布、载药量、包封率和体外释药等进行研究。结果:正交设计确定微球制备的最优处方工艺条件为PLGA质量浓度400g·L-1,PVA质量浓度20g·L-1,搅拌速度10000rpm;制备得到的sCT微球外观形态良好,平均粒径为(31.92±3.10)μm,载药量和包封率分别为(1.65±0.27)%和(41.44±3.39)%,28d的体外累积释放百分率在90%以上。结论:采用复乳-液中干燥法制备sCT微球是可行的,且工艺简单,重现性良好。
Objective：To prepare salcatonin（sCT）polyactic-co-glycolic acid（PLGA）microspheres and obverse its characteristics and in vitro release so as to provide scientific evidences for sCT sustained-release agent. Methods：Double emulsion in-liquid drying was adopted and PLGA was the material for design was used to optimize the formula technological condition the preparation of sCT microspheres. L9（3^4）orthogonal of microspheres preparation,and moreover to study morphology,particle size distribution, drug loading, encapsulation rate and in vitro release of prepared microspheres, etc. Results：L9（3^4）orthogonal design determined that the optimized formula technological condition of microspheres preparation was PLAG 400 g· L^-1 in quality concentration, PVA 20 g· L^-1 in quality concentration and 10 000 rpm in mixing speed. The prepared sCT microspheres was good in morphology, mean particle diameter （31.92±3.10）um, drug loading and encapsulation rate （1.65±0.27）% and （41.44±3.39）% respectively, and cumulative drug release in vitro of microspheres above 90% within 28d. Conclusion ： Double emulsion in-liquid drying is feasible in preparation of sCT microspheres.
出处
《世界中西医结合杂志》
2008年第8期457-459,共3页
World Journal of Integrated Traditional and Western Medicine
基金
山西省科技基础条件平台建设项目(No.2005091016)
